Track the BioAge Labs, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €480.1m. The latest transaction was disclosed on 1 July 2026 (Levée d'options). Among the most active insiders: Barton Shane. All data is free.
33
Insider Decl.
n/a
Thresholds
€2m
3 ops.
Buy Volume
€4m
4 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BioAge Labs, Inc. Buy (bullish), based on 8 analysts. Average price target: US$35.63.
33Σ signal
Buys €2m€4m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
18,000 shares@ US$6.5719.6% of flowCommon StockSEC:0001210905-25-000006:0
25 of 33 declarations
About BioAge Labs, Inc.
BioAge Labs, Inc. is a biotechnology company focused on developing therapies to extend lifespan by targeting the mechanisms of aging. It is listed on the XNAS market.